Loading clinical trials...
Loading clinical trials...
A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Conditions
Interventions
ASP1951
pembrolizumab
Locations
32
United States
Arizona Clinical Research Cent
Tucson, Arizona, United States
University of California
Sacramento, California, United States
University of Florida, Davis C
Gainesville, Florida, United States
Emory University
Atlanta, Georgia, United States
Augusta University
Augusta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Start Date
January 14, 2019
Primary Completion Date
July 6, 2023
Completion Date
July 6, 2023
Last Updated
November 1, 2024
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
NCT06760819
Lead Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions